Immune persistence after different polio sequential immunization schedules in Chinese infants.

Zhao, Ting; Li, Jing; Huang, Teng; Ying, Zhi-Fang; Che, Yan-Chun; Zhao, Zhi-Mei; Fu, Yu-Ting; Tao, Jun-Hui; Yang, Qing-Hai; Wei, Ding-Kai; Li, Guo-Liang; Yi, Li; Zhao, Yu-Ping; Chen, Hong-Bo; Wang, Jian-Feng; Jiang, Rui-Ju; Yu, Lei; Cai, Wei; Yang, Wei; Xie, Ming-Xue

Trivalent oral poliovirus vaccine (tOPV) has been withdrawn and instead an inactivated poliovirus vaccine (IPV) and bivalent type 1 and type 3 OPV (bOPV) sequential immunization schedule has been implemented since 2016, but no immune persistence data are available for this polio vaccination strategy. This study aimed to assess immune persistence following different polio sequential immunization schedules. Venous blood was collected at 24, 36, and 48 months of age from participants who had completed sequential schedules of combined IPV and OPV in phase III clinical trials. The serum neutralizing antibody titers against poliovirus were determined, and the poliovirus-specific antibody-positive rates were evaluated. A total of 1104 participants were enrolled in this study. The positive rates of poliovirus type 1- and type 3-specific antibodies among the sequential immunization groups showed no significant difference at 24, 36, or 48 months of age. The positive rates of poliovirus type 2-specific antibody in the IPV-IPV-tOPV group at all time points were nearly 100%, which was significantly higher than the corresponding rates in other immunization groups (IPV-bOPV-bOPV and IPV-IPV-bOPV). Immunization schedules involving one or two doses of IPV followed by bOPV failed to maintain a high positive rate for poliovirus type 2-specific antibody.

POLIO; CLINICAL trials; IMMUNIZATION; ANTIBODY titer; INFANTS; ORAL vaccines

NPJ Vaccines, 2024, Vol 9, Issue 1, p1

2059-0105

Academic Journal

10.1038/s41541-024-00831-1